Evaluation of Sun's Scoring System Use in Post-pancraticodoudenectomy Pancreatic Fistula

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-01-01

Study Completion Date

2025-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluation of sun scoring system for predication of pancreatic fistula after Pancreaticoduodenectomy to facilitate timely intervention after Pancreaticoduodenectomy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Textbook Outcome as a Composite Outcome Measure in Laparoscopic Pancreaticoduodenectomy

NCT05616403

Pancreatic Neoplasms

COMPLETED

A Study on the Occurrence Time of Grade-B Pancreatic Fistula After Pancreatoduodenectomy

NCT05667272

Postoperative Pancreatic Fistula

UNKNOWN

Evaluation of Prognosis and Prognostic Scores in Geriatric Patients With Acute Pancreatitis

NCT02223325

Acute Pancreatitis

UNKNOWN

Acute Pancreatitis : Comparison of Various Scores in Predicting Severity and Outcome

NCT06240338

Acute Pancreatitis

NOT_YET_RECRUITING

Focused Ultrasound for the Treatment of Pancreatic Cancer - an International Registry

NCT05010226

Pancreatic Cancer Focused Ultrasound

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pancreaticoduodenectomy is the only option curative intended in the treatment of resectable pancreatic ductal adenocarcinomas, duodenal carcinoma, ampullary carcinoma, lower common bile duct cholangiocarcinoma,. It is still associated with very high morbidity and mortality. \[1\]. Pancreatic cancer ranks as the seventh leading cause of cancer-related death worldwide, and the fourth among other cancers\[2,3\]. Pancreatic fistula(PF) is one of the most important complications after Pancreaticoduodenectomy, with an incidence of about 10% to 28%.\[4\].There are multiple risk factors for the predication of development of pancreatic fistula after pancreaticoduodenectomy which include soft gland texture, non-pancreatic cancer non-chronic pancreatitis pathology, small pancreatic duct diameter (\<3 mm), and high intraoperative blood loss (\>1000 mL) , excess intraoperative fluid administration and increased pancreatic parenchymal remnant volume \[5,6,7\]. Other reported risk factors as increased body mass index (BMI), poor preoperative nutrition, and male gender which preoperative may lead to pancreatic fistula \[8.9\]. Recent studies are deficient in evaluation and predication of pancreatic fistula . So the interest of our study to evaluate and predicate the risk factors and management of pancreatic fistula after Pancreaticoduodenectomy .

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Risk Scoring System for Prediction of Pancreatic Fistula Post PD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All the cases indicated for Pancreaticoduedenectomy with :

1. age less than 70 years.
2. resectable tumour,
3. fitness patients

Exclusion Criteria

* 1\_patients with jaundice with serum bilirubin above 200mml/dl. 2\_patients with bleeding tendency until corrected. 3\_patients with advanced and metastatic malignancy. 4\_patients with cardiopulmonary diseases.

Minimum Eligible Age

25 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No